towards improved death receptor targeted therapy for ... - TI Pharma

TRAIL and Hsp90 inhibition
19. Palacios C, Lopez‐Perez AI, Lopez‐Rivas A. Down‐regulation of RIP expression by 17‐
dimethylaminoethylamino‐17‐demethoxygeldanamycin promotes TRAIL‐induced
apoptosis in breast tumor cells. Cancer Lett 2010; 287(2):207‐215.
20. Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D et al. Molecular
determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor‐related
apoptosis‐inducing ligand. J Biol Chem 2005; 280(49):40599‐40608.
21. Azijli K, Yuvaraj S, Peppelenbosch MP, Wurdinger T, Dekker H, Joore J et al. Kinome
profiling of non‐canonical TRAIL signaling reveals RIP1‐Src‐STAT3 dependent invasion in
resistant non‐small cell lung cancer cells. J Cell Sci 2012.
22. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC et al. Regulation of
survivin function by Hsp90. Proc Natl Acad Sci U S A 2003; 100(24):13791‐13796.
23. Siegelin MD, Habel A, Gaiser T. 17‐AAG sensitized malignant glioma cells to death‐receptor
mediated apoptosis. Neurobiol Dis 2009; 33(2):243‐249.
24. Vasilevskaya IA, O'Dwyer PJ. 17‐Allylamino‐17‐demethoxygeldanamycin overcomes TRAIL
resistance in colon cancer cell lines. Biochem Pharmacol 2005; 70(4):580‐589.
25. Burrows F, Zhang H, Kamal A. Hsp90 activation and cell cycle regulation. Cell Cycle 2004;
3(12):1530‐1536.
26. de CG. Heat shock protein 90 regulates the metaphase‐anaphase transition in a polo‐like
kinase‐dependent manner. Cancer Res 2004; 64(15):5106‐5112.
27. Georgakis GV, Li Y, Rassidakis GZ, Martinez‐Valdez H, Medeiros LJ, Younes A. Inhibition of
heat shock protein 90 function by 17‐allylamino‐17‐demethoxy‐geldanamycin in Hodgkin's
lymphoma cells down‐regulates Akt kinase, dephosphorylates extracellular signal‐
regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006;
12(2):584‐590.
28. Arya R, Mallik M, Lakhotia SC. Heat shock genes ‐ integrating cell survival and death. J
Biosci 2007; 32(3):595‐610.
29. Eid MA, Lewis RW, Abdel‐Mageed AB, Kumar MV. Reduced response of prostate cancer
cells to TRAIL is modulated by NFkappaB‐mediated inhibition of caspases and Bid
activation. Int J Oncol 2002; 21(1):111‐117.
30. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. Inhibition of nuclear factor
kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998;
91(12):4624‐4631.
31. Zhang L, Fang B. Mechanisms of resistance to TRAIL‐induced apoptosis in cancer. Cancer
Gene Ther 2005; 12(3):228‐237.
32. Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR et al. The alkylphospholipid perifosine
induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of
the extrinsic apoptotic pathway. Mol Cancer Ther 2007; 6(7):2029‐2038.
33. Belyanskaya LL, Ziogas A, Hopkins‐Donaldson S, Kurtz S, Simon HU, Stahel R et al. TRAIL‐
induced survival and proliferation of SCLC cells is mediated by ERK and dependent on
TRAIL‐R2/DR5 expression in the absence of caspase‐8. Lung Cancer 2008; 60(3):355‐365.
34. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D et al. TRAIL promotes the
survival and proliferation of primary human vascular endothelial cells by activating the Akt
and ERK pathways. Circulation 2003; 107(17):2250‐2256.
35. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock
protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2012; 1823(3):742‐755.
‐ 97 ‐